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Sustained B‑cell activation is an important mechanism contributing to B‑cell lymphoma (BCL). We 
aimed to validate four previously reported B‑cell activation markers predictive of BCL risk (sCD23, 
sCD27, sCD30, and CXCL13) and to examine their possible mediating effects on the association 
between anthropometric and lifestyle factors and major BCL subtypes. Pre‑diagnostic serum levels 
were measured for 517 BCL cases and 525 controls in a nested case–control study. The odds ratios of 
BCL were 6.2 in the highest versus lowest quartile for sCD23, 2.6 for sCD30, 4.2 for sCD27, and 2.6 
for CXCL13. Higher levels of all markers were associated with increased risk of chronic lymphocytic 
leukemia (CLL), follicular lymphoma (FL), and diffuse large B‑cell lymphoma (DLBCL). Following 
mutual adjustment for the other immune markers, sCD23 remained associated with all subtypes 
and CXCL13 with FL and DLBCL. The associations of sCD23 with CLL and DLBCL and CXCL13 with 
DLBCL persisted among cases sampled > 9 years before diagnosis. sCD23 showed a good predictive 
ability (area under the curve = 0.80) for CLL, in particular among older, male participants. sCD23 and 
CXCL13 showed a mediating effect between body mass index (positive) and DLBCL risk, while CXCL13 
contributed to the association between physical activity (inverse) and DLBCL. Our data suggest a 
role of B‑cell activation in BCL development and a mediating role of the immune system for lifestyle 
factors.
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B-cell lymphomas (BCL) are an etiologically, clinically, and histologically heterogeneous group of malignant dis-
eases of B lymphocytes. Immunodeficiency and autoimmunity are strong B-cell lymphoma risk factors. Chronic 
B-cell activation is suspected to be an important mechanism contributing to the accumulation of genetic errors 
that can lead to  lymphomagenesis1. Increased serum/plasma levels of molecules involved in B-cell activation, 
among which soluble (s)CD23, sCD27, sCD30, sCD44, and CXCL13, have been associated with the development 
of acquired immune deficiency syndrome (AIDS)-related  BCL2–7. Recently, studies within general population 
cohorts incorporating serologic measurements of cytokines, chemokines, and other immune markers have pro-
vided important evidence supporting a role for subtle immunologic effects in lymphomagenesis even among 
non-immunocompromised  individuals8–12. Elevated serum levels of sCD23, sCD27, sCD30, and CXCL13 have 
subsequently been shown to be associated with BCL development in immunocompetent  individuals8–12.
The risk of BCL has been associated with lifestyle, viral, and environmental  factors13,14. A large study from 
the International Lymphoma Epidemiology Consortium (InterLymph) showed several risk/protective factors 
for Non-Hodgkin lymphoma  subtypes13. These included a family history of hematologic malignancy, history of 
autoimmune disease, hepatitis virus C (HCV) infection, body mass index (BMI), height, smoking, and occupa-
tion, which were all associated with increased risk of NHL and/or one of its subtypes (CLL, FL, or DLBCL), 
while alcohol intake (≥ 1 drink per month), better socio-economic position (SEP), history of atopic disease, 
and recreational sun exposure were linked with reduced risks. Given the central role of the immune system in 
lymphomagenesis, most risk factors may influence BCL risk through modulation of the immune  function15. 
Indeed, diet and obesity have an important influence on the immune system as immune functions are sensitive 
to both under- and over-nutrition16. Obesity promotes increased production of cytokines and  leptin16, and the 
latter, in turn, has been shown to enhance B-cell  survival17.
Infection with hepatitis virus B (HBV) and HCV correlate with high  sCD3018–20 and  sCD2321,22 serum levels. 
In a study including HCV-infected patients, with and without BCL, a signature involving sCD27, sIL-2Rα, gamma 
globulins, and complement factor 4 was associated with the presence of overt BCL in HCV-infected  patients23.
Moreover, exposure to environmental factors suspected to be acting as lymphomagens (i.e. trichloroethylene 
and 2,3,7,8-tetrachlorodibenzo-p-dioxin) altered sCD27 and sCD30 plasma  levels24,25. Studies have shown that 
alcohol consumption may be associated with a decreased risk of  BCL13. Alcohol is associated with dysregulation 
of cytokines and chemokines, which may mediate alcohol-induced tumor promotion. Alcohol may also affect 
transcription factors and signaling pathways that regulate the expression/function of cytokines and  chemokines26. 
Alcohol abuse impairs both the number and function of B cells. Chronic alcohol consumption reduces B-cell 
numbers, decreases antigen-specific antibody responses, increases the production of auto-antibodies, and inter-
feres with B-cell development and maturation. Moreover, alcohol’s impact on T and B cells increases the risk of 
infections (e.g., pneumonia, HIV infection, hepatitis C virus infection, and tuberculosis)27. However, to date, 
the direct mediating effect of immune markers on the association between these factors and BCL risk has not 
been investigated in a prospective setting.
In our previous study among participants of two prospective cohorts (32 BCL cases overlap with cases 
included in the present study), which also included a meta-analysis of published data on sCD27 and sCD30, 
we reported a highly consistent association between these markers and increased risk of BCL  subtypes12. Pre-
diagnostic sCD23 was a strong predictive marker (area under the curve (AUC) = 0.88) for diagnosis of CLL (179 
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CLL cases overlap with cases included in the present study)28. So far, previous studies have limitations in terms of 
sample size, in particular for BCL subtypes, limiting their power to detect associations of moderate magnitude.
In the present study, we aimed to extend our previous findings using a much larger population within the 
European Prospective Investigation into Cancer and Nutrition (EPIC) population to examine the relationship 
between pre-diagnostically level of the most promising previously reported B-cell activation markers (sCD23, 
sCD27, sCD30, and CXCL13) and subsequent development of BCL major subtypes, i.e. diffuse large B-cell lym-
phoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). Moreover, we aimed at 
exploring the potential clinical utility of these markers for screening and their possible mediating effects on the 
association between anthropometric and lifestyle factors and BCL subtypes.
Results
Table 1 shows the characteristics of the study population. Overall, case and control subjects did not differ with 
regard to risk factors and covariates. Median time between recruitment (i.e., blood collection) in the study and 
diagnosis of BCL was 9 years (range, 0.2–19). Blood levels of all B-cell activation markers were significantly 
higher in cases compared to controls (Table 1). Spearman correlations were calculated between the various 
Table 1.  General characteristics of B-cell lymphoma cases and controls. a Mean (SD); Body mass index (BMI); 
diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL). 
b one CLL and 9 controls lacked paired samples ; Due to limited sample volume, sCD27 and CXCL13 were not 
measured in 5 and 11 samples, respectively. So sample size for those markers are as: Matched analyses: CD27 
(511 pairs), CXCL13 (506 pairs). Unmatched analyses: CD27 (515 cases/522 controls), CXCL13 (511/520). 
c Median (min–max). Bold: statistically significant at p-value ≤ 0.05.
Matched pairs, n = 1,032 All subjects, n = 1,042b
Cases, n = 516 Controls, n = 516 p Cases, n = 517 Controls, n = 525 p
Agea 55.2 (9.11) 55.2 (9.11) 0.99 55.2 (9.09) 55.2 (9.08) 0.92
Female, n (%) 301 (58.3) 301 (58.3) 1.00 301 (58.2) 305 (58.1) 1.00
Height,  cma 166.3 (9.09) 165.8 (9.39) 0.35 166.3 (9.09) 165.8 (9.38) 0.37
BMI, kg/m2a 26.6 (4.40) 26.3 (3.92) 0.26 26.6 (4.39) 26.3 (3.91) 0.26
Education, n (%) 0.40 0.41
None 41 (7.9) 37 (7.2) 41 (7.9) 38 (7.2)
Primary school 175 (33.9) 159 (30.8) 176 (34) 162 (30.9)
Technical/professional school 131 (25.4) 121 (23.4) 131 (25.3) 123 (23.4)
Secondary school 74 (14.3) 92 (17.8) 74 (14.3) 92 (17.5)
University/college 95 (18.4) 107 (20.7) 95 (18.4) 110 (21)
Smoking status, n (%) 0.98 0.98
Never smoker 238 (46.1) 241 (46.7) 238 (46) 244 (46.5)
Former smoker 168 (32.6) 167 (32.4) 169 (32.7) 169 (32.2)
Current smoker 110 (21.3) 108 (20.9) 110 (21.3) 112 (21.3)
Alcohol intake, gr/dayc 5.5 (0–124.2) 4.7 (0–235.2) 0.56 5.5 (0–124.2) 4.7 (0–235.2) 0.67
Physical activity, n (%) 0.93 0.96
Inactive 136 (26.4) 135 (26.2) 137 (26.5) 137 (26.1)
Moderately inactive 159 (30.8) 166 (32.2) 159 (30.8) 168 (32)
Moderately active 110 (21.3) 112 (21.7) 110 (21.3) 113 (21.5)
Active 111 (21.5) 103 (20) 111 (21.5) 107 (20.4)
Country, n (%) 1.00 1.00
Italy 100 (19.4) 100 (19.4) 100 (19.3) 104 (19.8)
Spain 95 (18.4) 95 (18.4) 95 (18.4) 96 (18.3)
UK 143 (27.7) 143 (27.7) 144 (27.9) 143 (27.2)
Netherlands 96 (18.6) 96 (18.6) 96 (18.6) 97 (18.5)
Greece 22 (4.3) 22 (4.3) 22 (4.3) 22 (4.2)
Germany 60 (11.6) 60 (11.6) 60 (11.6) 63 (12)
sCD23, pg/mLa 8.15 (0.66) 7.71 (0.39) < 0.0001 8.15 (0.66) 7.71 (0.38) < 0.0001
sCD30, ng/mla 2.85 (0.54) 2.67 (0.35) < 0.0001 2.85 (0.54) 2.67 (0.35) < 0.0001
sCD27, U/mla 3.59 (0.39) 3.46 (0.30) < 0.0001 3.60 (0.40) 3.46 (0.31) < 0.0001
CXCL13, pg/mLa 3.38 (0.81) 3.08 (0.59) < 0.0001 3.37 (0.81) 3.09 (0.59) < 0.0001
Lymphoma subtypes, n (%)
DLBCL 174 (33.7) – 174 (33.7) –
CLL 210 (40.7) – 211 (40.8) –
FL 132 (25.6) – 132 (25.5) –
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immune markers among the total BCL cases, controls, and by lymphoma subtypes, ranging from 0.14 to 0.63 
(Supplementary Table 1). We found the lowest correlations between these immune markers among controls, while 
sCD30 was highly correlated with sCD27 in CLL, and with all other markers in FL. Levels of the markers were 
positively correlated with age in both cases and controls except for CXCL13 in control subjects (Supplementary 
Fig. 1). Compared to male participants, female subjects had slightly higher levels of sCD30 and CXCL13 that 
met the threshold of statistical significance (Supplementary Table 2). There was no significant difference in levels 
of the markers in different countries except for CXCL13 (Supplementary Table 2).
Association between immune markers and lymphoma development. Multivariable conditional 
logistic regression analyses for all BCL cases showed a significant association for all markers when analyzed as 
categorized variables (Table 2). The subtype-specific analyses rendered similar results except for a non-signif-
icantly increased risk of CLL with elevated levels of CXCL13 (Table 2). To account for the correlation between 
the markers, all markers were also modeled together. The combined multivariable models showed a significant 
association between sCD23 and all three BCL subtypes, and between CXCL13 and FL and DLBCL (Table 3). 
Moreover, we found a borderline significant association between sCD27 and all three BCL subtypes.
Analyses using continuous measures of the markers showed similar results to the categorical analyses (Sup-
plementary Table 3).
Analyses stratified by time‑to‑diagnosis (TTD). To explore the possibility of reverse causation, asso-
ciations of the markers with risk of BCL and subtypes were further stratified by median (9 years) duration of 
time between blood donation and diagnosis of BCL. Unconditional logistic regression among subjects diag-
nosed ≤ 9 years from the time of blood collection essentially showed similar associations as presented in Table 2. 
Subjects diagnosed more than 9 years from the time of blood collection with elevated levels of sCD23 and sCD27 
showed an increased risk of CLL, while increased levels of all markers were associated with higher risk of DLBCL 
(Supplementary Table 4). In the combined model (including all markers together), associations of sCD23 with 
CLL and CXCL13, sCD23, and sCD27 with DLBCL remained significant.
Table 2.  Multivariable conditional analyses: odds ratio (OR) and 95% confidence interval (CI) for individual 
immune marker (categorical variable) and B-cell lymphoma and histological subtypes. B-cell lymphoma 
(BCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), chronic lymphocytic leukemia 
(CLL); number of cases/controls (N); adjusted for BMI, education, smoking, alcohol intake, and physical 
activity; Quartiles were calculated based on the distribution in control subjects; tests for trend (p) were 
calculated using the quartile number as a continuous variable. Bold: statistically significant at p-value ≤ 0.05.
Marker’s
level
BCL CLL FL DLBCL
N OR (95% CI) N OR (95% CI) N OR (95% CI) N OR (95% CI)
sCD23, pg/mL
Q1 6.345–7.45 63/130 Ref 16/54 Ref 20/27 Ref 27/49 Ref
Q2 7.451–7.72 75/128 1.5 (0.95–2.38) 19/48 1.22 (0.43–2.9) 24/42 0.77 (0.3–1.89) 32/38 1.86 (0.85–4.1)
Q3 7.721–7.972 104/128 1.9 (1.25–2.98) 33/51 2.34 (1.03–5.3) 34/33 1.57 (0.7–3.46) 37/44 1.56 (0.7–3.39)
Q4 7.973–9.879 274/130 6.2 (3.95–9.74) 142/57 10.5 (4.7–23.4) 54/30 3.88 (1.54–9.8) 78/43 4.10 (1.82–9.2)
P 516/516 < 0.0001 210/210 < 0.0001 132/132 0.001 174/174 0.001
sCD30, ng/ml
Q1 1.555–2.434 98/129 Ref 37/45 Ref 31/40 Ref 30/44 Ref
Q2 2.435–2.639 96/128 1.11 (0.74–1.66) 39/52 1.1 (0.49–2.20) 19/34 0.92 (0.4–2.02) 38/42 2.6 (1.15–5.91)
Q3 2.640–2.856 122/132 1.36 (0.91–2.06) 52/54 1.42 (0.71–2.8) 27/26 1.56 (0.66–3.6) 43/52 1.99 (0.87–4.6)
Q4 2.857–5.621 200/127 2.62 (1.71–3.95) 82/59 2.14 (1.1–4.24) 55/32 3.0 (1.39–6.53) 63/36 5.87 (2.4–14.7)
P 516/516 < 0.0001 210/210 0.01 132/132 0.003 174/174 0.001
sCD27, U/ml
Q1 2.152–3.27 91/128 Ref 35/49 Ref 24/31 Ref 32/48 Ref
Q2 3.271–3.459 100/126 1.38 (0.89–2.1) 36/53 1.14 (0.56–2.3) 29/37 1.15 (0.45–2.85) 35/36 1.87 (0.86–4.1)
Q3 3.46–3.645 125/131 2.0 (1.25–3.19) 51/51 2.1 (0.98–4.5) 28/33 1.7 (0.61–4.74) 46/47 1.98 (0.85–4.6)
Q4 3.646–5.707 195/126 4.24 (2.56–7.0) 85/54 4.63 (2.0–10.7) 50/30 4.29 (1.46–12.7) 60/42 4.32 (1.7–10.9)
P 511/511 < 0.0001 207/207 < 0.0001 131/131 0.004 173/173 0.003
CXCL13, pg/mL
Q1 1.116–2.785 96/129 Ref 52/55 Ref 21/31 Ref 23/43 Ref
Q2 2.786–3.086 94/127 1.2 (0.81–1.84) 44/57 0.9 (0.46–1.75) 25/36 1.11 (0.49–2.5) 25/34 1.93 (0.84–4.4)
Q3 3.087–3.444 113/125 1.45 (0.95–2.2) 45/39 1.35 (0.7–2.75) 20/32 1.02 (0.4–2.58) 48/54 2.15 (1.0–4.62)
Q4 3.445–6.809 203/125 2.6 (1.74–3.94) 63/53 1.39 (0.7–2.7) 62/29 4.01 (1.7–9.37) 78/43 4.67 (2.14–10)
P 506/506 < 0.0001 204/204 0.17 128/128 0.0004 174/174 < 0.0001
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The correlation between marker levels and time to diagnosis was evaluated. These analyses revealed higher 
levels of the markers in those cases with blood drawing closer to the diagnosis date (Fig. 1) except for sCD23 
and sCD27 among DLBCL cases, which may suggest that serum levels of these markers are impacted by the 
disease itself.
Receiver operating characteristic (ROC) and test performance analysis. The AUC, as a measure 
of how well a marker (or a group of markers) predict the development of BCL subtype, was calculated by tenfold 
cross-validation. We found an AUC of 0.80 for a model including sCD23 as a predictor of CLL. Addition of 
other markers to the model did not significantly increase the prediction ability for CLL (Supplementary Table 5). 
sCD23 levels showed the highest prediction ability for CLL among male participants (AUC = 0.85, p = 0.0003) 
and more particularly those older than 60 years as indicated by an AUC 0.88 (p = 0.02) (Supplementary Table 6). 
sCD23 and CXCL13 showed a lower predictive ability for FL (AUC ~ 0.60) and DLBCL (AUC ~ 0.63) compared 
with CLL and addition of other markers did not significantly increase the AUCs for these subtypes (Supplemen-
tary Table 5).
While the AUCs gave an overall picture of the behavior of the markers across all cutoff values, there remains 
a practical need to determine the specific cutoff value that could be used for individuals requiring screening. 
Therefore, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for dif-
ferent cut-off values of sCD23 for the prediction of CLL, FL, and DLBCL and cut-off values of CXCL13 for 
the prediction of FL and DLBCL were determined (Supplementary Table 7–8). Generally, there is a trade-off 
between sensitivity and specificity. Using the cut-off value showing the highest specificity, subjects with sCD23 
levels ≥ 3,608 pg/mL appeared to have a 70% probability to develop CLL after 9 years (Fig. 2a, Supplementary 
Table 7), the probability being slightly higher for male (0.76) than for female (0.62) participants (Fig. 2b, c, Sup-
plementary Table 7). When analyzing sCD23 and CXCL13 test accuracy for DLBCL and FL, it was observed 
that despite the specificity of sCD23 being the same for FL and DLBCL, PPVs were low compared to CLL (Sup-
plementary Table 8).
Mediation analyses. Finally, to evaluate the hypothesis that immune markers act as a mediator on the 
causal pathway between known risk factors and B-cell lymphoma, a causal mediation analysis was conducted. 
Actual analyses were performed if (1) the risk factors were significantly associated with immune markers (Sup-
plementary Table 9, model M) and (2) immune markers were found to be significantly associated with lym-
phoma subtypes in our combined models (Table 3). Selection of possible risk factors for mediation analyses 
was based on a large pooled study from 20 case–control  studies13. Although, most of these associations were 
only suggestive and not significant in EPIC (Model X in Supplementary Table 9), the cohort can still help to 
Table 3.  Odds ratio (OR) and 95% confidence interval (CI) for combined immune marker (categorical 
variables) and B-cell lymphoma and histological subtypes. B-cell lymphoma (BCL), diffuse large B-cell 
lymphoma (DLBCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL); adjusted for BMI, 
education, smoking, alcohol intake, and physical activity; to see the immune marker levels associated with each 




sCD23 1.46 (0.90–2.37) 1.83 (1.16–2.90) 4.85 (2.98–7.90) < 0.0001
sCD30 1.01 (0.64–1.59) 0.84 (0.53–1.35) 0.99 (0.56–1.66) 0.72
sCD27 1.1 (0.68–1.79) 1.36 (0.80–2.35) 2.35 (1.28–4.30) 0.001
CXCL13 1.17 (0.74–1.85) 1.24 (0.78–1.96) 1.96 (1.23–3.14) 0.001
CLL
sCD23 1.19 (0.44–3.17) 2.32 (0.99–5.46) 10.3 (4.29–24.8) < 0.0001
sCD30 1.19 (0.48–3.0) 0.80 (0.33–1.96) 0.93 (0.36–2.40) 0.67
sCD27 0.79 (0.32–1.95) 1.09 (0.40–2.95) 1.68 (0.54–2.25) 0.10
CXCL13 0.87 (0.38–2.02) 1.10 (0.45–2.70) 0.80 (0.33–1.91) 0.99
FL
sCD23 0.72 (0.26–1.99) 1.53 (0.62–3.79) 2.81 (0.90–8.75) 0.02
sCD30 0.81 (0.32–2.03) 1.39 (0.50–3.88) 1.0 (0.34–2.92) 0.97
sCD27 1.07 (0.34–3.36) 0.97 (0.25–3.73) 2.74 (0.65–11.6) 0.08
CXCL13 0.97 (0.39–2.45) 0.93 (0.33–2.63) 3.41 (1.26–9.22) 0.01
DLBCL
sCD23 1.70 (0.71–4.06) 1.19 (0.52–2.74) 2.60 (1.04–6.48) 0.05
sCD30 2.33 (0.95–5.75) 1.23 (0.49–3.07) 2.43 (0.83–7.10) 0.41
sCD27 1.40 (0.57–3.41) 1.72 (0.65–4.55) 3.58 (1.15–11.1) 0.08
CXCL13 1.88 (0.78–4.55) 1.84 (0.81–4.19) 3.60 (1.50–8.68) 0.01
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understand potential mechanisms due to the prospective framework. Therefore, results of the mediation analy-
sis should be seen as suggestive mediated associations. Positive association between BMI and DLBCL (aver-
age causal mediation effect (ACME) = 0.02) mediated through both sCD23 and CXCL13 (Table 4). We found 
a lower risk of DLBCL (ACME = − 0.02) with physical activity mediated through CXCL13. Finally, there was a 
trend toward significance for a protective effect of alcohol intake (ACME = − 0.05) mediated through sCD23 on 
CLL and for a protective effect of physical activity (ACME = − 0.01) mediated through CXCL13 on FL (Table 4). 
Figure 1.  Correlation between serum level of immune markers and time to diagnosis (TTD) for different BCL 
subtype and controls; TTD for controls was calculated based on diagnosis date of the index cases.
Figure 2.  ROC curve and test accuracy parameters of sCD23 for cutoff at 30th (≥ 1832 pg/mL), 60th 
(≥ 2,453 pg/mL), and 90th (≥ 3,608 pg/mL) deciles for CLL (A) and stratified by gender (B, C); ROC receiver 
operating characteristic, PPV positive predictive value, NPV negative predictive value.
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Sensitivity analysis were conducted to evaluate the robustness of the results from the causal mediation analysis. 
The analyses showed that as long as ρ was 0.4 or lower, the estimated mediated effects still had the same sign, 
indicating good robustness.
Discussion
In this prospective study, we determined the serum levels of previously reported lymphoma associated immune 
markers and investigated how these markers correlate to the future risk of BCL histological subtypes and if 
risk of lymphoma is mediated by these markers. From these results, we confirmed the association between 
pre-diagnostically measured B-cell activation markers (sCD23, sCD27, sCD30, and CXCL13) and subsequent 
development of major BCL  subtypes8–12,28,29. After adjustment for other immune markers, sCD23 remained 
significantly associated with all subtypes, while CXCL13 was found to be associated with FL and DLBCL only. 
The associations between sCD23 and CLL and DLBCL, and CXCL13 and DLBCL persisted among cases sampled 
more than 9 years before diagnosis, although the associations were attenuated in comparison to the findings from 
the models that covered the entire follow-up. sCD23 showed the highest prognostic value for CLL. In addition, 
we assessed for the first time, whether these markers may be mediating the causal pathway between several 
risk/protective factors and later lymphoma risk. Our results suggest that sCD23 and CXCL13 partly mediated 
the association between BMI (positive) and DLBCL risk, while lower levels of CXCL13 associated with higher 
physical activity and this partly explains the inverse association of physical activity and DLBCL risk. It should 
be noted that the measured biomarkers are individual markers in a complicated signaling milieu. Therefore 
any reported mediating effect for the marker itself should be interpreted as a proxy of the underlying biologic 
milieu that is captured by circulating levels of those molecules that is partly mediating the alleged associations.
We observed strong associations between sCD23, sCD27, sCD30, and CXCL13 in blood samples collected 
up to 19 years before diagnosis and risk of BCL development, consistent with previous  studies8–12,28,29. The asso-
ciations between sCD23 levels and development of BCL subtype were the most stable associations in this study, 
particularly for CLL, which was significant even more than 9 years before BCL diagnosis. In a recent study using 
the EPIC cohort with maximum 12.5 years TTD, ROC curve for the prediction or diagnosis of CLL indicates that 
sCD23 is a strong predictive marker (AUC = 0.88)30 which is consistent with our current finding of AUC = 0.80. 
The earlier study included 179 CLL cases that were also present in our study. AUC based on new cases only 
(maximum 19 years follow-up) was 0.73. Moreover, our study showed that sCD23 is apparently more predictive 
in men than in women for future risk of CLL. Little is known how sex-specific factors influence CLL incidence. 
Although androgen receptors play a part in lymphopoiesis, it is unclear how this relates to the sex differences in 
CLL. As second explanation, sex-specific somatic alterations in the non-pseudoautosomal and pseudoautosomal 
regions on chromosomes X and Y have also been suggested to influence CLL  incidence30.
CD23 is an integral membrane glycoprotein involved in IgE binding, and is found on mature B-cells, activated 
macrophages, eosinophils, follicular dendritic cells, and platelets. CD23 is expressed on the membrane in CLL, 
in some cases of FL, and primary mediastinal large B-cell lymphoma. CLL cells have a characteristic phenotype 
of  sIglow/CD19+/CD5+/CD23+31. CD23 has been widely used as a marker in the differential diagnosis of CLL 
versus mantle cell lymphoma. Its soluble form, sCD23, is released from activated B-cells and can itself induce 
further B-cell stimulation as well as function as a potent mitogenic growth factor. Many reports suggest that 
elevated CD23, either on neoplastic cell surfaces or as a soluble form, is a useful marker in either diagnosis or 
Table 4.  Average direct effect and causal mediation effect (mediated through B-cell activation markers) 
of known risk factors on B-cell lymphoma subtypes. Diffuse large B-cell lymphoma (DLBCL), follicular 
lymphoma (FL), chronic lymphocytic leukemia (CLL); Cases and control have been analyzed together; 
Correlation parameter (ρ) for mediated effect at which the sign of average causal mediation effect (ACME) is 
reversed; Effect estimates are the change in probability for moving the exposure variable from the reference 
category to the exposure category: alcohol intake: non-drinker (0) versus drinker (1), activity: first 3 
categories (0) versus active(1), and BMI: < 30 (0) versus ≥ 30 (1); * “average direct effect” shows the estimate for 
unmediated effect which is the effect from any other path except the mediated one; † significant at p = 0.065; 
‡ Shows the percentage of total effect mediated by the immune marker, it can be negative or greater than 100 
depend on direct and mediated effect magnitudes and directions. Bold: statistically significant at p-value ≤ 
0.05.
Average causal mediation effect ρ Average direct effect * Total effect Proportion mediated ‡
sCD23, CLL, n = 737
BMI 0.04 (− 0.006 to 0.09) 0.4 0.05 (− 0.03 to 0.12) 0.09 (− 0.01 to 0.18)† 0.44
Alcohol − 0.05 (− 0.10 to 0.003)† 0.4 0.01 (− 0.07 to 0.09) − 0.04 (− 0.14 to 0.06) 0.80
sCD23, DLBCL, n = 698
BMI 0.02 (0.002 to 0.04) 0.3 − 0.07 (− 0.14 to 0.02) − 0.05 (− 0.12 to 0.04) − 0.26
CXCL13, FL, n = 648
Physical activity − 0.01 (− 0.03 to 0.001)† 0.3 0.002 (− 0.07 to 0.08) − 0.01 (− 0.08 to 0.06) 0.23
CXCL13, DLBCL, n = 693
BMI 0.02 (0.0005 to 0.05) 0.4 − 0.07 (− 0.15 to 0.02) − 0.05 (− 0.12 to 0.04) − 0.34
Physical activity − 0.02 (− 0.05 to − 0.003) 0.3 0.01 (− 0.07 to 0.09) − 0.01 (− 0.09 to 0.07) 0.41
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prognosis of  BCL31. Assuming that increased levels of sCD23 are caused by early stages of disease, our results 
further support that sCD23 would act as a marker for early detection of  CLL28.
In a study within the Northern Sweden Health and Disease Study (NSHDS), B-cell activation markers were 
measured in two pre-diagnostic blood samples donated by 170 individuals before BCL diagnosis, along with 170 
matched cancer-free  controls29. The study showed that regardless of baseline B-cell activation marker concentra-
tion, BCL future risk was also associated with an increase of marker concentrations over time (slope). The predic-
tive ability of these markers for response to treatment as well as their prognostic value for disease progression in 
particular in the trajectory from monoclonal B-cell lymphocytosis (MBL), an asymptomatic condition in which 
small numbers of clonal B cells are detectable in blood, to CLL must be further assessed.
CXCL13 is a CXC subtype member of the chemokine superfamily and acts via its receptor CXCR5 as one of 
the most potent B-cell chemo-attractants. CXCL13 expression is observed in BCL and diseases with B-cell acti-
vation. We reported that higher levels of CXCL13 were associated with increased risk of DLBCL, independently 
of sCD23, even among subjects diagnosed > 9 years after study initiation. Our finding is consistent with a previ-
ous report within the NSHDS (42 DLBCL cases)29, the Women’s Health Initiative Observational Study cohort 
(138 DLBCL cases)8, and Nurses’ Health Study and Health Professionals Follow-up Study (107 DLBCL cases)32. 
This would argue against the idea that increased marker concentrations would be attributable to undiagnosed 
disease, considering that the median survival of DLBCL is expected to be only a few months if left  untreated29.
The fact that measured B-cell activation marker levels were higher in those cases with blood drawing closer 
to the diagnosis date may indicate the existence of undiagnosed lymphoproliferative disease, in particular for 
indolent BCL subtypes. On the other hand, this may also reflect biological processes involved in the onset of the 
disease, e.g. as a measure of the allostatic load on the B-cell compartment related to non-heritable factors such 
as lifestyle and environmental  factors18–25. Previous studies showed that elevated concentrations of these markers 
were associated with disease states related to immune system activation, such as autoimmune diseases, hepatitis 
C, and HIV  infection18–23. However, such information was not available on our subjects, except for data on HBV 
infection from only a minority of the subjects (n = 335).
Currently, no established screening programs for BCL development exist. Pre-diagnostic screening for risk 
factors of BCL in the general population has currently little clinical benefit. Moreover, cut-offs of marker levels 
to be used as a measure for disease progression have not been established yet. This would require the conduct of 
a large number of studies within various populations in order to establish normal levels and resulting in a more 
uniform reference for “abnormal” levels for use in clinical practice. In our view, the value of pre-diagnostic bio-
markers is potentially much larger in groups of patients that are already at elevated risk of developing BCL, such 
as those with a family history of lymphoma and immunocompromised patients (i.e., primary immunodeficiency 
disorders, PID). PID patients carry an eightfold increased risk of lymphoma compared to the general population. 
Patients who have higher levels of the markers may thus be recommended to start intensive follow-up, while 
individuals with lower level of the markers may be advised for a less intensive follow-up. However, usefulness of 
these markers must be examined and validated among those patients before they could be rationally employed 
by physicians to improve human health.
To our knowledge, this is the first study to assess the hypothesis of B-cell activation markers as mediators 
on the potential pathway between risk factors and later lymphoma development. BMI was associated with a 
significant increased risk of DLBCL mediated through sCD23 and CXCL13. There is no clear consensus on how 
obesity impacts B-cell development and function, but several studies point to an involvement of B-cells in adipose 
tissue inflammation associated with  obesity33–35. A further study in obese and non‐obese women revealed that 
body fat mass was positively correlated with total leukocyte, neutrophil, monocyte and lymphocyte  counts36. 
While T‐cell function was comparable between obese and non‐obese women, B-cell function was about 50% 
higher in the obese group.
Physical activity was associated with decreased risk of DLBCL and FL mediated through CXCL13. There has 
been evidence that moderate exercise is beneficial for the immune  system37. Exercise induced changes in the 
number and function of cell subsets involved in the innate (e.g., neutrophils, monocytes, and natural killer cells) 
and the adaptive immune system (e.g., T and B cells)37,38. It has been shown that exercise can reduce insulin, 
glucose, and insulin-like growth factors, which may influence the proliferation of tumor cells in general. Physical 
activity also plays role in the prevention of obesity and reduces the percentage of body  fat38. However, it is not 
clear if modulation of the immune system contributes to the potential antitumor properties of exercise.
Adaptive immune responses, also called acquired immunity, is characterized by antigen‐specific T‐cell prolif-
eration, immunological memory, B-cell activation, and production of antibodies. Evidence indicates that alcohol 
exposure can interfere with various aspects of the immune response and affect the different cellular components 
of the innate and/or adaptive immune system. Several studies reported that the number and function of B-cells 
are reduced by  alcohol26,27. In our study, sCD23 mediated the association between alcohol intake and decreased 
risk of CLL. A meta-analysis provided evidence for a favorable role of alcohol drinking on NHL  risk39. However, 
there is no clear biological explanation for this association.
A strength of our study is the relatively large number of incident cases of newly diagnosed major BCL sub-
types in a cohort of cancer-free individuals with pre-diagnostic blood samples and prospective follow-up times 
of up to 19 years. This enabled us to carry out specific analyses according to BCL subtypes. This is particularly 
relevant since there is growing evidence that lymphoma subtypes have different pathological and epidemiological 
 features13. However, limitations of our study should be considered when interpreting the results. We measured 
blood immune markers at a single time point, which may not reflect accurately the long-term B-cell activation 
status and may not capture the most important etiologic timing. We cannot exclude potential measurement 
errors derived from dietary questionnaires, which could lead to systematic and random errors when estimat-
ing alcohol intake. Likewise, anthropometric measures were ascertained at recruitment (with the exception of 
the Oxford, France and Norway cohorts—self-reported). Moreover, we cannot exclude the possible bias due to 
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unmeasured confounders (e.g., immune diseases and infections), which are well known risk factors of BCL. If an 
unmeasured confounder is related to several mediators this may have resulted in a bias in the mediation  results40. 
Due to the limited sample size, the results of this sensitivity analysis should be interpreted with caution. Notably, 
the measured immune markers are not only produced by those cell types considered to play pivotal roles in the 
immune system (lymphocytes), but also by fibroblasts, neutrophils, eosinophils, follicular dendritic cells, and 
platelets. So, blood levels of the markers may not necessarily reflect activity in the target tissue (lymph nodes)41.
In conclusion, increased B-cell activation marker levels present in blood years before BCL diagnosis, suggest 
a role of B-cell activation in BCL development at early stages. These may reflect a constitutional predisposi-
tion with shared underlying mechanisms for both indolent and aggressive lymphoma subtypes. Further studies 
investigating the biological and clinical impact of these markers are required. The mediating role of the immune 
function in the association between lifestyle factors and BCL also needs further examination.
Materials and methods
Study population. The EPIC study is a prospective cohort study involving 23 centers from ten European 
countries (Denmark, France, Germany, Greece, the Netherlands, Italy, Norway, United Kingdom, Spain and 
Sweden) that was designed to investigate the potential relationships between diet, nutritional status, lifestyle and 
environmental factors and the incidence of cancer and other chronic  diseases42. Over 500,000 healthy subjects 
in the age range 35–70 were recruited in the study during 1992–2000. The rationale, complete methodology and 
study design of the EPIC study have been described  previously42,43. The ethical review boards from the Interna-
tional Agency for Research on Cancer and all local participating centers approved the study and all participants 
gave their informed consent. The study was conducted in accordance with the approved guidelines.
Standardized lifestyle, medical and personal history, and diet questionnaires were collected from the partici-
pants, and a blood sample was taken at enrollment. Anthropometric measures were measured at recruitment 
(except for France, Oxford and Norway who collected self-reporting data). Within 2 h of blood collection, blood 
samples were processed for the isolation of buffy coats and other fractions. Samples were transported on dry ice 
to the laboratory and stored at − 80 °C before analyses were performed.
Incident lymphoma cancer cases were identified by population cancer registries for Denmark, Italy, The 
Netherlands, Norway, Spain, Sweden and the United Kingdom. A combination of methods was used in France, 
Germany and Greece, as detailed  previously42. Originally, the diagnosis of lymphoma cases was based on the 
ICD-O-2. All lymphoma cases were subsequently reclassified according to the SEER ICD-O-3 morphology 
 codes44. For each incident BCL case identified within the cohort by December 2012, one random control was 
selected among all cohort members alive and free of cancer at the time of diagnosis of the index case, matched 
by country, center, gender, age at recruitment (± 12 months), date of blood collection (± 3 months), time of blood 
collection (± 3 h), and fasting at blood collection.
The current analysis was based on 516 case–control pairs for which a blood sample was available consisting 
of 174 DLBCL, 132 FL, and 210 CLL (including small lymphocytic leukemia) cases. For one CLL case and 9 
controls, paired samples were missing. These subjects were included only in unconditional logistic analyses.
Inclusion of etiological factors for FL, DLBCL, CLL subtypes. Previously known BCL risk and pro-
tective  factors13 that were available in EPIC were included in the study. These included BMI, height, smoking, 
education as proxy for SEP, alcohol intake and physical activity. The physical activity assessment included occu-
pation as well as average recreational and household activity.
Measurement of immune markers. Serum levels of sCD23, sCD27, sCD30, and CXCL13 were meas-
ured by ELISA for all samples (eBioscience, USA: BMS286INST, BMS240INST kits, and R&D Systems, USA: 
DCD230 and DCX130 kits). Assays were performed in duplicate and according to the manufacturers’ proto-
cols. All laboratory personnel were blinded with regard to case–control status. Matched case–control sets were 
assayed next to each other on the same plate in the same batch and quality control samples were run in duplicate 
along with the case–control sets in each batch. Inter- and intra-assay coefficients of variation were 2.2% and 3.1% 
for sCD23, 8.9% and 8.8% for sCD27, 4.8% and 7.3% for sCD30, and 5.2% and 6.8% for CXCL13.
Statistical analysis. Marker levels measured out of range of the calibration curve (sCD23 = 6.3%, 
sCD30 = 0.8%, sCD27 = 0.5%, CXCL13 = 19.1%) and missing values of smoking status (2%), education (7%), 
alcohol intake (0.4%), physical activity (2.7%) covariates (Supplementary Table 10) were imputed based on a 
maximum likelihood estimation method which was informed by the observed correlation structure within 
the  data45. Blood levels of soluble markers were log transformed to normalize their distributions. Differences 
between cases and controls in baseline continuous covariates were assessed using the paired t test, and by χ2-
test, for categorical variables. Spearman rank correlation was used to measure the degree of correlation between 
markers.
Odds ratios (OR) and 95% confidence intervals (95% CI) for the subtypes of BCL in relation to immune mark-
ers (as continuous variables) were calculated by conditional logistic regression (CLR). The models were adjusted 
for BMI (kg/m2, continuous), alcohol intake (g/day; continuous), smoking status (never, former, current), physi-
cal activity levels based on the Cambridge Physical Activity Index (inactive, moderately inactive, moderately 
active, active)46 and educational level (none, primary, technical/professional, secondary, university/college). 
Quartiles of immune marker concentrations were calculated based on the distribution in control subjects, and 
CLR models were used to estimate the association between quartiles of marker levels and risk of BCL subtypes 
(first quartile as reference category). Tests for trend were calculated using the quartile number as a continuous 
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variable. All markers were also modeled together (combined multivariable model) as it may be possible that one 
marker serves as a surrogate of another.
Associations of the markers with risk of BCL and subtypes were additionally stratified by median duration 
of time between blood donation and diagnosis of BCL (time-to-diagnosis: TTD) to explore the possibility of 
reverse causation. In these analyses, to preserve statistical power, subtype cases were compared to all controls 
and (unconditional) models additionally adjusted for matching variables (i.e., country, gender, and age at recruit-
ment) and plate number.
Receiver operating characteristic (ROC) analysis and AUC comparisons were used to determine the dis-
criminative ability of the markers separately or in combination with other markers. The AUCs was corrected 
for biases due to overfitting by tenfold cross-validation. For each fold, the AUC was calculated, and the mean of 
the fold AUCs was the cross-validated AUC estimate. Four objective measures of test performance were further 
calculated, namely, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) 
for different cut-off values of the markers found to be informative for future risk of  BCL47. Cut-off values were 
calculated based on deciles of ranked level of the markers in control subjects.
Causal mediation analysis was applied to study the average causal mediation effect (ACME) and the average 
direct (unmediated) effect (ADE) of immune markers linking risk factors to  lymphoma48. The effect estimates 
represent the change in probability that the subject develops lymphoma when moving the exposure variable from 
the reference category to the exposure category via the mediated or direct paths. Further, the analysis provides 
an estimate of the proportion of the total effect of exposure on lymphoma development mediated through the 
measured marker. Included exposure variables were smoking: non-smoker at recruitment (0) vs. smoker (1), 
alcohol intake: non-drinker (0) vs. drinker (1), physical activity: first 3 categories (0) vs. active(1), education: 
categories primary school or lower/ technical/ vocational school (0) vs. secondary school/ university/college 
(1), BMI: < 30 (0) versus ≥ 30 (1), and height: < country median (0) versus ≥ country median (1). We fitted two 
statistical models, the mediator (M) linear model for the conditional distribution of the mediator M given the 
risk factor X and a set of the covariates C; f(M | X, C), and the outcome (Y) logistic model for the conditional 
distribution of the outcome Y given X, M , and C; f(Y | X, M, C). These models were fitted separately and then 
their fitted objects comprised the main inputs to the mediate function, which computes the estimated ACME and 
other quantities of interest under these models and the sequential ignorability assumption. Mediation analyses 
were applied only for the risk factors significantly associated with immune markers and for the immune markers 
found to be significantly associated with lymphoma subtypes in our combined models (sCD23 and CXCL13). 
Adjustments were made for country, sex, and age. Models for each risk factor were additionally adjusted for 
other risk factors. There was no significant interaction between the risk factors and sCD23 and CXCL13. Quasi-
Bayesian confidence intervals were  determined49. Sensitivity analyses were performed for deviations from the 
sequential ignorability assumption (that in particular implies no unmeasured pre-sample collection confound-
ers), with deviations measured by the correlation ρ between the errors in the mediation and the outcome models. 
In the presence of confounders which affect both the mediator and the outcome, we expect that the sequential 
ignorability assumption is violated and ρ is no longer  zero48. A large critical ρ value reversing the sign of ACME 
indicates the violation of ignorability  assumption49.
Statistical analyses were performed using the R 3.4.1 language and environment (The R Foundation for Statis-
tical Computing, Vienna, Austria) and SAS (version 9.4; SAS institute, USA). The R package mediation (4.1.2) was 
used for causal mediation  analysis49. All p values are two-sided, with p < 0.05 considered as statistically significant.
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